Christopher M Marano1, Clifford I Workman2, Christopher H Lyman2, Cynthia A Munro2, Michael A Kraut3, Gwenn S Smith2. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: cmarano1@jhmi.edu. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. 3. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
OBJECTIVES: Recent positron emission tomography studies of cerebral glucose metabolism have identified the functional neural circuitry associated with mood and cognitive responses to antidepressant treatment in late life depression (LLD). The structural alterations in these networks are not well understood. The present study used magnetic resonance (MR) imaging and voxel-based morphometry to evaluate the association between gray matter volumes and changes in mood symptoms and cognitive function with treatment with the antidepressant citalopram. DESIGN: Open-label trial with baseline brain MR scan. Mood and cognitive assessments performed at baseline and during citalopram treatment. SETTING: Outpatient clinics of an academic medical center. PARTICIPANTS: 17 previously unmedicated patients age 55 years or older with a major depressive episode and 17 non-depressed comparison subjects. INTERVENTION: 12-week trial of flexibly dosed citalopram. MEASUREMENTS: Gray matter volumes, Hamilton Depression Rating Scale, California Verbal Learning Test, Delis-Kaplan Executive Function System. RESULTS: In LLD, higher gray matter volumes in the cingulate gyrus, superior and middle frontal gyri, middle temporal gyrus, and precuneus was associated with greater mood improvement. Higher gray matter volumes in primarily frontal areas were associated with greater improvement in verbal memory and verbal fluency performance. CONCLUSIONS: Associations with antidepressant induced improvements in mood and cognition were observed in several brain regions previously correlated with normalization of glucose metabolism after citalopram treatment in LLD. Future studies will investigate molecular mechanisms underlying these associations (e.g., beta-amyloid, inflammation, glutamate).
OBJECTIVES: Recent positron emission tomography studies of cerebral glucose metabolism have identified the functional neural circuitry associated with mood and cognitive responses to antidepressant treatment in late life depression (LLD). The structural alterations in these networks are not well understood. The present study used magnetic resonance (MR) imaging and voxel-based morphometry to evaluate the association between gray matter volumes and changes in mood symptoms and cognitive function with treatment with the antidepressant citalopram. DESIGN: Open-label trial with baseline brain MR scan. Mood and cognitive assessments performed at baseline and during citalopram treatment. SETTING:Outpatient clinics of an academic medical center. PARTICIPANTS: 17 previously unmedicated patients age 55 years or older with a major depressive episode and 17 non-depressed comparison subjects. INTERVENTION: 12-week trial of flexibly dosed citalopram. MEASUREMENTS: Gray matter volumes, Hamilton Depression Rating Scale, California Verbal Learning Test, Delis-Kaplan Executive Function System. RESULTS: In LLD, higher gray matter volumes in the cingulate gyrus, superior and middle frontal gyri, middle temporal gyrus, and precuneus was associated with greater mood improvement. Higher gray matter volumes in primarily frontal areas were associated with greater improvement in verbal memory and verbal fluency performance. CONCLUSIONS: Associations with antidepressant induced improvements in mood and cognition were observed in several brain regions previously correlated with normalization of glucose metabolism after citalopram treatment in LLD. Future studies will investigate molecular mechanisms underlying these associations (e.g., beta-amyloid, inflammation, glutamate).
Authors: K R Krishnan; W M McDonald; P R Escalona; P M Doraiswamy; C Na; M M Husain; G S Figiel; O B Boyko; E H Ellinwood; C B Nemeroff Journal: Arch Gen Psychiatry Date: 1992-07
Authors: D C Steffens; C E Byrum; D R McQuoid; D L Greenberg; M E Payne; T F Blitchington; J R MacFall; K R Krishnan Journal: Biol Psychiatry Date: 2000-08-15 Impact factor: 13.382
Authors: Ming-Hong Hsieh; Douglas R McQuoid; Robert M Levy; Martha E Payne; James R MacFall; David C Steffens Journal: Int J Geriatr Psychiatry Date: 2002-06 Impact factor: 3.485
Authors: Sandra Bell-McGinty; Meryl A Butters; Carolyn Cidis Meltzer; Phil J Greer; Charles F Reynolds; James T Becker Journal: Am J Psychiatry Date: 2002-08 Impact factor: 18.112
Authors: K Droppa; H T Karim; D L Tudorascu; J F Karp; C F Reynolds; H J Aizenstein; M A Butters Journal: J Psychiatr Res Date: 2017-08-08 Impact factor: 4.791
Authors: Sungeun Melanie Lee; Michaela M Milillo; Beatrix Krause-Sorio; Prabha Siddarth; Lisa Kilpatrick; Katherine L Narr; Jonathan P Jacobs; Helen Lavretsky Journal: Int J Environ Res Public Health Date: 2022-02-19 Impact factor: 3.390
Authors: Rajapillai L I Pillai; Ashwin Malhotra; Deborah D Rupert; Bennett Weschler; John C Williams; Mengru Zhang; Jie Yang; J John Mann; Maria A Oquendo; Ramin V Parsey; Christine DeLorenzo Journal: Hum Brain Mapp Date: 2017-11-27 Impact factor: 5.038